BiotechTube

Trifarotene Cream 0.005% + AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG + AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acne Vulgaris

Conditions

Acne Vulgaris

Trial Timeline

Jun 20, 2024 → Nov 9, 2024

NCT ID
NCT06733402

About Trifarotene Cream 0.005% + AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG + AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT + Placebo

Trifarotene Cream 0.005% + AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG + AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT + Placebo is a phase 1 stage product being developed by Sun Pharmaceutical for Acne Vulgaris. The current trial status is completed. This product is registered under clinical trial identifier NCT06733402. Target conditions include Acne Vulgaris.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06733402Phase 1Completed

Competing Products

20 competing products in Acne Vulgaris

See all competitors
ProductCompanyStageHype Score
Olumacostat Glasaretil Gel, 5.0%Eli LillyPhase 3
77
HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 PlaceboHoth TherapeuticsPhase 2
44
Tretinoin Gel Microsphere, 0.1% + RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% + Placebo ControlSun PharmaceuticalPhase 1
33
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% + Acanya® Gel, 1.2%/2.5% + Vehicle of test productSun PharmaceuticalPhase 1
33
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + Duac® Topical Gel + Placebo Topical GelSun PharmaceuticalPhase 1
33
Adapalene Gel 0.1% + Placebo Control + Differin® Gel (Adapalene 0.1%, Galderma)Sun PharmaceuticalPhase 1
33
Trifarotene Cream 0.005% + Placebo + AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)Sun PharmaceuticalPhase 1
33
Adapalene/BP gel, 0.3%/2.5% + EPIDUO® FORTE + PlaceboSun PharmaceuticalPhase 1
33
ADPS topical product + Placebo ControlSun PharmaceuticalPhase 2
52
IsotretinoinSun PharmaceuticalApproved
85
Winlevi (Clascoterone) cream 1%Sun PharmaceuticalApproved
85
Adapalene Gel 0.3% + Differin® + PlaceboSun PharmaceuticalPhase 1
33
CLPG Topical Gel 1% + Clindamycin + PlaceboSun PharmaceuticalPhase 1
33
Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% + Epiduo® Gel + PlaceboSun PharmaceuticalPhase 1
33
Test. + Aczone Gel 5% + PlaceboSun PharmaceuticalPhase 1
33
Clindamycin and Benzoyl Peroxide Gel 1%5% + BenzaClin® Topical Gel + PlaceboSun PharmaceuticalPhase 1
33
Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% + Onexton™ Gel + PlaceboSun PharmaceuticalPhase 1
33
Clindamycin Phosphate + Clindamycin Phosphate RLD + PlacebosSun PharmaceuticalPhase 1
33
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% + CABTREO Topical Gel + Placebo ControlSun PharmaceuticalPhase 1
33
Tretinoin cream, 0.05% + RETIN-A® (tretinoin) cream, 0.05% + Vehicle of the test productSun PharmaceuticalPhase 1
33

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85